22nd of March 2024

Dear Prescribers,

Notification of important information relating to ARX-Dabigatran

Arrotex Pharmaceuticals Pty Ltd, as the supplier of ARX-Dabigatran, wish to provide you with important information in relation to prescribing ARX-Dabigatran.

Arrotex wishes to inform any individuals who prescribe Dabigatran, or who treat patients who are required to take Dabigatran, the availability of educational materials regarding Dabigatran.

These educational materials include:

- Prescriber guide for "Prevention of venous thromboembolic events (VTE) following elective total hip or knee replacement surgery"
- Prescriber guide for "Stroke prevention in atrial fibrillation, treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (DVT/PE)"

In addition, a Patient alert card/leaflet is available which should be with the patient and/or caregiver at all times which outlines their ARX-Dabigatran intake to their healthcare professional.

These educational materials are available by:

- Downloading from the Arrotex website at https://arrotex.com.au/arx-dabigatran-rmm
- Requesting a copy from Arrotex Medical Information either by phone (1800 195 055) or via email (patient.safety@arrotex.com.au)

We request this information is provided to all relevant staff members within your organisation.

If you have any questions regarding the above, please do not hesitate to contact the Arrotex Medical Information team.

Yours sincerely,



Ivan Medved
General Manager Scientific Affairs
Arrotex Pharmaceuticals